Saltar al contenido
Merck

Influence of camel milk on the hepatitis C virus burden of infected patients.

Experimental and therapeutic medicine (2017-04-18)
Esmail Mohamad El-Fakharany, Nawal Abd El-Baky, Mustafa Hassan Linjawi, Abdullah Abdelhafiz Aljaddawi, Tahya Hussein Saleem, Ahmed Yassine Nassar, Ashraf Osman, Elrashdy Moustafa Redwan
RESUMEN

Hepatitis C virus (HCV) infection represents a world health problem and no protective vaccine or effective drug currently exists. For economic reasons, many patients use traditional medicines to control the infection. In Egypt, camel milk is one of the traditional medicines widely consumed by patients infected with HCV. The present study aimed to evaluate the efficacy of camel milk in the treatment of patients infected with HCV. Whole camel milk from a local farm was administered to patients for 4 months (250 ml/day/patient). Patient sera were collected prior to and following camel milk drinking, and three markers were set-up for sera-evaluation. The three markers indicating the effect of camel milk on HCV infection were: Liver function assays [alanine aminotransferase (ALT) and aspartate aminotransferase (AST)]; a viral load assay; and anti-HCV antibodies profile and isotyping against synthetic HCV epitopes. Camel milk demonstrated the ability to improve general fatigue, health and liver function (ALT and AST levels); ALT was reduced in ~88% of patients and AST was reduced in all patients subsequent to drinking camel milk for four months. The majority of patients responded positively to camel milk treatment; RNA viral load decreased in 13 out of the 17 patients (76.47%) and one patient exhibited undetected viremia following camel milk treatment. The anti-HCV antibodies profile and isotyping were significantly decreased (P<0.05) in immunoglobulin (Ig)G1 following treatment in 70-76% of patients. However, the treatment was ineffective in 23.53% of patients who experienced no reduction in RNA viral load following treatment with camel milk. In conclusion, whole camel milk treatment demonstrated efficacy in vivo; the viral load in the majority of patient sera was reduced and the IgG isotype profile was converted to Th1 immunity.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anti-Human IgG4−Biotin antibody, Mouse monoclonal, clone HP-6025, purified from hybridoma cell culture
Sigma-Aldrich
Anti-Human IgG1−Biotin antibody, Mouse monoclonal, clone 8c/6-39, purified from hybridoma cell culture
Sigma-Aldrich
Anti-Human IgG2−Biotin antibody, Mouse monoclonal, clone HP-6014, purified from hybridoma cell culture
Sigma-Aldrich
Anticuerpo anti-IgG3−biotina humana, monoclonal de ratón antibody produced in mouse, clone HP-6050, purified from hybridoma cell culture